Answers are grounded in this paper and cite their sources.
In the treatment of advanced EGFR-mutant non-small cell lung cancer (NSCLC), third-generation EGFR tyrosine kinase inhibitors (TKIs) are established as the standard first-line therapy. However, the presence of TP53 co-mutations is prevalent and consistently correlates with earlier resistance and poorer survival outcomes. TP53 mutations facilitate EGFR-TKI resistance through multiple interconnected mechanisms, including defective DNA damage repair, genomic and chromosomal instability, activation of the cGAS-STING pathway, epithelial-mesenchymal transition, reprogramming of downstream signaling pathways such as PI3K/AKT, NF-κB, and STAT3, broader clonal evolution toward EGFR-independent resistance, and lineage transformation, particularly in the presence of concurrent RB1 alterations. Retrospective cohort studies and meta-analyses indicate reduced progression-free and overall survival rates associated with EGFR-TKI monotherapy, particularly in certain TP53 subtypes such as gain-of-function and exon 8 mutations. Prospective investigations suggest that intensified treatment regimens may mitigate these adverse outcomes to some extent. In the TOP trial, the combination of osimertinib and chemotherapy demonstrated improved progression-free survival compared to osimertinib monotherapy in treatment-naive patients with concurrent TP53 mutations. Similarly, the ACROSS2 study reported benefits with the combination of aumolertinib and chemotherapy. Furthermore, anti-angiogenic combinations and amivantamab-based therapies have shown promising efficacy in TP53-mutant subgroups, albeit with increased toxicity. Current evidence positions TP53 co-mutation as a negative prognostic marker for monotherapy and as a potential biomarker for risk-adapted combination therapies, highlighting the necessity for prospective stratification based on TP53 subtype. Future research should focus on conducting prospective clinical trials that target specific TP53 mutation subtypes in EGFR-mutant NSCLC. Also, this should include the integration of dynamic ctDNA clearance monitoring through liquid biopsy and the development of novel combination therapeutic strategies. The ultimate goal is to achieve a paradigm shift from empirical treatment to individualized precision medicine, guided by the molecular characteristics of TP53.
No takes yet. Share an insight, caveat, or question.
Ding et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: